<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-919" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Adapalene</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tolaymat</surname>
            <given-names>Leila</given-names>
          </name>
          <aff>Mayo Clinic Jacksonville</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Dearborn</surname>
            <given-names>Heidi</given-names>
          </name>
          <aff>San Antonio Uniformed Services Health Education Consortium</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Zito</surname>
            <given-names>Patrick M.</given-names>
          </name>
          <aff>University of Miami; Miller School of Medicine</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Leila Tolaymat declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Heidi Dearborn declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Patrick Zito declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>26</day>
          <month>6</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-919.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Adapalene is a topical retinoid with FDA approval for treating acne vulgaris. Retinoids are vitamin A derivatives that are typically described in terms of generations with increased specificity of retinoic acid receptor (RAR) affinity with later generations. Clinicians use retinoids are used to treat a wide variety of skin disorders. Adapalene also has multiple off-label therapeutic applications, including the treatment of verrucae, molluscum contagiosum, Darier disease, Fox-Fordyce disease, Dowling-Degos disease, photoaging, pigmentary disorders, actinic keratoses, and alopecia areata. This activity outlines the indications, contraindications, interactions, monitoring, and other therapeutic information pertinent to members of an interprofessional team in the care of patients on adapalene therapy.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the approved indications for adapalene.</p></list-item><list-item><p>Describe the mechanism of action of adapalene.</p></list-item><list-item><p>Summarize the adverse effect profile of adapalene.</p></list-item><list-item><p>Review interprofessional team strategies for improving care coordination and communication to improve patient outcomes using adapalene.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=919&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=919">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-919.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Adapalene is a topical retinoid that is FDA-approved for treating acne vulgaris.<xref ref-type="bibr" rid="article-919.r1">[1]</xref><xref ref-type="bibr" rid="article-919.r2">[2]</xref>&#x000a0;Like other retinoids, adapalene has been used off-label for various skin conditions, including verrucae, molluscum contagiosum, Darier disease, Fox-Fordyce disease, Dowling-Degos disease, photoaging, pigmentary disorders such as melasma and post-inflammatory hyperpigmentation, actinic keratoses, and alopecia areata.<xref ref-type="bibr" rid="article-919.r3">[3]</xref>&#x000a0;Additionally, adapalene and adapalene analogs are investigated for potential anti-microbial, anti-cancer, and neuroprotective effects.<xref ref-type="bibr" rid="article-919.r4">[4]</xref></p>
        <p>Adapalene was initially FDA-approved in 1996 for acne in patients 12 years of age or older. The FDA-approved adapalene 0.1% gel as an over-the-counter acne treatment in patients 12 and older in 2016. Formulations of adapalene 0.1% lotion, cream, and 0.3% gel are available by prescription only.</p>
        <p>Retinoids are vitamin A derivatives that are typically described in terms of generations with increased specificity of retinoic acid receptor (RAR) affinity with later generations. Adapalene is a third-generation synthetic retinoid developed to improve the side effect profile compared to tretinoin. This first-generation topical retinoid more closely resembles natural vitamin A in structure.<xref ref-type="bibr" rid="article-919.r4">[4]</xref>&#x000a0;Second-generation retinoids are oral medications. The primary representative of the second generation is acitretin, which has enhanced benefits to the skin but has limited therapeutic use due to the significant risk of toxicity and is contraindicated for people of childbearing potential.<xref ref-type="bibr" rid="article-919.r5">[5]</xref></p>
        <p>Third-generation retinoids include adapalene, tazarotene, and bexarotene. Of the third generation, bexarotene is a synthetic retinoid that binds exclusively to retinoid X receptors (RXR). Adapalene and tazarotene have higher specificity for RAR-gamma and RAR-beta and do not interact with RXRs making them suitable for topical administration with minimal systemic absorption.<xref ref-type="bibr" rid="article-919.r6">[6]</xref>&#x000a0;Trifarotene is a fourth-generation topical retinoid FDA-approved in 2019 for treating acne with a 20-fold greater affinity for RAR-gamma, the most dominant subtype in the skin, and has no affinity for RXR receptors.<xref ref-type="bibr" rid="article-919.r7">[7]</xref></p>
        <p>Retinoids modulate epidermal growth and differentiation, stimulate humoral and cellular immunity, decrease the inflammatory response, and reduce cell proliferation. The diverse biological actions of retinoids make them ideal for treating various skin disorders.<xref ref-type="bibr" rid="article-919.r5">[5]</xref>&#x000a0;Topical retinoids are recommended as first-line therapy to treat acne vulgaris, alone or in combination with other acne medications.<xref ref-type="bibr" rid="article-919.r8">[8]</xref>&#x000a0;Topical retinoids used in treating acne vulgaris include adapalene, tretinoin, tazarotene, and trifarotene. Topical retinoids target two pathogenic mechanisms of acne vulgaris: microcomedone formation, which is the precursor of all forms of acne lesions, and the inflammatory response.<xref ref-type="bibr" rid="article-919.r6">[6]</xref></p>
        <p>Conventional teaching indicates that the retinoids used to treat acne have varying grades of efficacy and tolerability. Adapalene is perceived to be the least effective but the best tolerated. Tretinoin is understood to have moderate efficacy and tolerability. Tazarotene has maximum efficacy but is not tolerated due to skin irritation. Currently, conventional teaching does not yet compare trifarotene with prior generations; however, it has increased the ability to induce gene expression compared to tazarotene.<xref ref-type="bibr" rid="article-919.r7">[7]</xref></p>
        <p>Despite these conventions, studies support that adapalene is more efficacious in treating acne vulgaris than other retinoids. A meta-analysis including five randomized controlled trials suggested that adapalene 0.1% gel had similar efficacy but enhanced tolerability in acne treatment compared to tretinoin 0.025% gel.&#x000a0;Adapalene has also been compared to tretinoin in a vehicle formulation of microsphere gel, which allows for tretinoin to be delivered primarily to the epidermis to decrease irritation and increase tolerability. A randomized controlled trial of tolerability, safety, and efficacy of adapalene gel 0.1% and tretinoin 0.1% microsphere gel revealed that the efficacy was comparable in total, non-inflammatory, and inflammatory lesions. However, the adapalene patient group exhibited significantly enhanced cutaneous tolerability.<xref ref-type="bibr" rid="article-919.r9">[9]</xref></p>
        <p>Adapalene also performs well when compared to tazarotene. In a 12-week randomized, evaluator-blinded study comparing adapalene 0.3% gel and tazarotene 0.1% gel, each group had a clinically significant reduction in total lesion counts. A 61% reduction in acne lesions occurred with the administration of adapalene, with a 57% reduction in the tazarotene group. Adapalene, 0.3% gel, had equivalent efficacy to tazarotene 0.1% gel. However, patients using adapalene experienced less irritation than patients in the tazarotene-treated group.<xref ref-type="bibr" rid="article-919.r10">[10]</xref></p>
        <p>Adapalene has additional advantages when compared to other retinoids. Adapalene is a more stable molecule, which leads to less concern for molecular photodegradation, allowing for use during daylight hours. This stability contrasts with both tretinoin and tazarotene, which are photolabile. The stability of adapalene allows for use in combination with benzoyl peroxide, which has a synergist effect. A randomized double-blinded study of topical adapalene 0.3%-benzoyl peroxide 2.5% demonstrated significantly greater efficacy in patients with moderate-to-severe inflammatory, non-nodulocystic acne. With the synergistic effect of benzoyl peroxide, adapalene 0.3% increases patient treatment options for moderate to severe acne.<xref ref-type="bibr" rid="article-919.r2">[2]</xref><xref ref-type="bibr" rid="article-919.r11">[11]</xref></p>
      </sec>
      <sec id="article-919.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Adapalene is a third-generation topical retinoid prescribed for the treatment of acne vulgaris.<xref ref-type="bibr" rid="article-919.r12">[12]</xref>&#x000a0;Adapalene is a naphthoic acid derivative designed to be more structurally rigid&#x000a0;than&#x000a0;previous retinoid generations, which decreases its ability to bind multiple retinoid receptors, thus reducing off-target effects. Adapalene is an active metabolite and therefore requires no metabolic conversion. The adamantane nucleus is the chemical moiety that allows adapalene to attach to RAR-beta and RAR-gamma. This complex binds DNA through retinoic acid response elements and induces gene transcription, leading to downstream keratinocyte proliferation and differentiation. As a result, adapalene decreases microcomedone formations, exfoliates mature comedones, and has anti-inflammatory effects.<xref ref-type="bibr" rid="article-919.r4">[4]</xref><xref ref-type="bibr" rid="article-919.r9">[9]</xref>&#x000a0;Of&#x000a0;note, the adamantane nucleus is a component found in multiple other drugs, including antivirals and anti-hypoglycemic agents. Adapalene and newer analogs are under investigation for new potential therapeutic uses due to the antiproliferative,&#x000a0;antibacterial, and neuroprotective activity attributed to the adamantane moiety.<xref ref-type="bibr" rid="article-919.r13">[13]</xref><xref ref-type="bibr" rid="article-919.r4">[4]</xref></p>
        <p>The pathogenesis of acne vulgaris is multifactorial. However, the main factors associated with acneiform lesion development are follicular hyperkeratinization, sebum production by sebaceous glands, and inflammation. In acne-prone patients, keratinocytes accumulate in the lumen of the hair follicle due to increased keratinocyte proliferation and cohesiveness, leading to the formation of a keratotic plug, resulting in the microcomedone. The microcomedone is the precursor to all visible acne lesions like open comedones, closed comedones, inflammatory papules, pustules, and nodulocystic lesions. Adapalene normalizes the differentiation of follicular epithelial cells to prevent microcomedone formation. In addition, adapalene, when applied topically, penetrates the hair follicles due to its lipophilic nature.</p>
        <p>In addition to follicular hyperkeratinization, acne is also a disorder associated with inflammation. Propionibacterium acnes is a gram-positive, anaerobic rod found in the sebaceous follicle. P. acnes is present in both acne-prone individuals and those without acne. The hypothesis is that there may be differences in the strains of P. acnes or in the host response to P. acnes, which leads to its varying degrees of pathogenicity. P. acnes release mediators that contribute to comedones rupture and stimulate inflammatory cells. P. acnes stimulates the toll-like receptor II (TLR-2) pathway, which releases pro-inflammatory modulators. This action leads to neutrophil recruitment and the release of enzymes that result in follicular epithelium rupture. One mediator, IL-12, promotes a TH1 immune response. Adapalene is thought to suppress polymorphonuclear lymphocyte chemotaxis and down-regulate 15-lipoxygenase and TLR-2, contributing to its anti-inflammatory effects. The anti-inflammatory action of adapalene is comparable to betamethasone-17-valerate and indomethacin.<xref ref-type="bibr" rid="article-919.r9">[9]</xref><xref ref-type="bibr" rid="article-919.r6">[6]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:&#x000a0;</bold>Systemic exposure of adapalene following topical application of adapalene gel is minimal.&#x000a0;</p>
        <p><bold>Distribution: </bold>Adapalene drug molecules are distributed in&#x000a0;the epidermis and dermis.<xref ref-type="bibr" rid="article-919.r14">[14]</xref></p>
        <p><bold>Metabolism:&#x000a0;</bold>Information regarding adapalene metabolism in humans is unavailable, although it is known to accumulate in the liver.&#x000a0;The major products of metabolism are glucuronides. Approximately 25% of the&#x000a0;adapalene&#x000a0;is metabolized, and the rest is excreted in unchanged form.</p>
        <p><bold>Excretion:</bold>&#x000a0;The terminal apparent half-life is 7 to 51 hours. Excretion of adapalene is primarily through the biliary route.</p>
      </sec>
      <sec id="article-919.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Adapalene is applied to a clean face once daily in the morning or at bedtime. The patient should wash the face with a gentle cleanser and allow the face to dry thoroughly. Then a pea-sized amount of adapalene should be applied as a thin layer to the entire face. Avoiding application to eyelids, lips, and mucous membranes is necessary. Patients can apply an oil-free moisturizer over adapalene to help decrease the risk of irritation. As there is a risk of photosensitivity with topical retinoids, the clinician should also recommend an oil-free sunscreen and warn the patient against excessive sun exposure.</p>
        <p>One reason for treatment failure with topical retinoids is the initial skin irritation that occurs and maximizes in intensity within two weeks of treatment. This initial mild irritation can lead to the discontinuation of therapy.<xref ref-type="bibr" rid="article-919.r15">[15]</xref> There are several options for treatment regimens to decrease the initial irritation as the skin acclimates to daily use. Options include application every other day, short contact therapy, or choosing a different drug vehicle.<xref ref-type="bibr" rid="article-919.r6">[6]</xref></p>
        <p>An investigation in modulating treatment regimens with adapalene 0.1%-benzoyl peroxide 2.5% combination in the first four weeks demonstrated no difference in efficacy outcomes at 12 weeks. The treatment regimens investigated were topical nightly application, limited exposure application of 3 hours, every other night application, and nightly application with a gentle moisturizer.<xref ref-type="bibr" rid="article-919.r11">[11]</xref></p>
        <p>
<bold>Use in Specific Patient Populations</bold>
</p>
        <p><bold>Patients with Renal Impairment: </bold>No information regarding the use of adapalene in patients with renal impairment is provided in product labeling.&#x000a0;</p>
        <p><bold>Patients with Hepatic Impairment: </bold>No information regarding the use of adapalene in patients with&#x000a0;hepatic impairment is provided in product labeling.</p>
        <p><bold>Pregnancy Considerations:&#x000a0;</bold>Adapalene was pregnancy category C under the prior FDA pregnancy classification system and should be avoided in pregnant patients. . Oral exposure of pregnant animals to high doses of third-generation retinoids resulted in retinoid embryopathies. Topical administration of adapalene results in minimal systemic absorption, with less than 0.01% absorbed systemically and clearance from plasma within 72 hours of application.&#x000a0;The most sensitive adverse effect of retinoids is possible teratogenicity. Vitamin A is essential for embryo-fetal development. Both deficiencies and overabundance can disrupt normal development. First and second-generation retinoids are known to cause retinoid embryopathies with oral administration. Topically applied retinoids, including first-generation tretinoin, have minimal systemic absorption, and third- and fourth-generation retinoids are designed to minimize off-target effects. Concern for teratogenicity was first raised because three reports to the FDA from 1986 to 1989 highlight holoprosencephaly in infants exposed to topical retinoids in utero. Subsequent case series and observational cohorts did not corroborate the initial reports.<xref ref-type="bibr" rid="article-919.r7">[7]</xref>&#x000a0;</p>
        <p>A recent systematic literature review and meta-analysis evaluating first-trimester exposure to topical retinoids demonstrated no clear increase in the risk of retinoid embryopathy.&#x000a0;However, the lack of epidemiologic data is&#x000a0;reason enough to approach the use of topical retinoids during pregnancy with caution. Topical retinoids are not currently recommended during pregnancy.&#x000a0;Therefore, adapalene should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.<xref ref-type="bibr" rid="article-919.r5">[5]</xref><xref ref-type="bibr" rid="article-919.r16">[16]</xref>&#x000a0;</p>
        <p><bold>Breastfeeding Considerations:&#x000a0; </bold>The use of topical adapalene has not been evaluated during breastfeeding. Adapalene is probably a low risk to the nursing infant because it is poorly absorbed after topical application, and blood levels are minimal with prolonged therapy. However, clinicians should advise breastfeeding mothers that adapalene should not be applied to the nipple area and ensure that the infant's skin does not come into direct contact with skin areas treated with adapalene. Clinicians should generally avoid prescribing during breastfeeding&#x000a0;due to potential risks to the infant.<xref ref-type="bibr" rid="article-919.r17">[17]</xref></p>
      </sec>
      <sec id="article-919.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Adverse reactions reported from adapalene include photosensitivity, irritation, redness, dryness, itching, and burning. These are usually mild adverse events.<xref ref-type="bibr" rid="article-919.r8">[8]</xref><xref ref-type="bibr" rid="article-919.r18">[18]</xref></p>
        <p>Adapalene is less irritating compared to other topical retinoids. In a blinded, randomized, controlled, parallel-group study of 591 acne patients, a combined safety analysis conducted in the United States and Europe compared adapalene 0.1% gel and tretinoin 0.025% gel. The number of patients discontinuing the study due to adverse events was about twice as high in those using tretinoin (2.4%) compared to adapalene (1.3%). There were no systemic adverse reactions noted in the study. Most of the adverse reactions observed were related to skin irritation. Multiple other studies have demonstrated similar findings.<xref ref-type="bibr" rid="article-919.r9">[9]</xref><xref ref-type="bibr" rid="article-919.r6">[6]</xref>&#x000a0;</p>
        <p>Adapalene 0.1% and 0.3% have also been compared to tazarotene in multiple studies showing adapalene to be non-inferior in efficacy and demonstrated superior tolerability.<xref ref-type="bibr" rid="article-919.r10">[10]</xref><xref ref-type="bibr" rid="article-919.r19">[19]</xref>&#x000a0;The enhanced tolerability of adapalene has been attributed, in part, to the selective affinity to the nuclear RAR-beta and RAR-gamma receptors, as opposed to RAR-alpha. The decreased risk of skin irritation may contribute to better long-term compliance. Exposure to ultraviolet light should be minimized in patients using adapalene gel. Patients exposed to high levels of sun exposure and sensitive to sunlight should exercise caution. Using sunscreen and protective clothing over adapalene-treated areas is suggested when patients cannot avoid exposure to the sunlight.<xref ref-type="bibr" rid="article-919.r4">[4]</xref></p>
        <p>Rare, severe allergic reactions characteristically demonstrate pruritus, facial edema, lip swelling, and eyelid swelling.<xref ref-type="bibr" rid="article-919.r15">[15]</xref><xref ref-type="bibr" rid="article-919.r20">[20]</xref>&#x000a0;If a patient experiences anaphylactic reactions with symptoms, including facial swelling, hives, chest pain, or shortness of breath, adapalene should be discontinued, and the patient should seek immediate medical evaluation.</p>
      </sec>
      <sec id="article-919.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Contraindications include a history of hypersensitivity to adapalene or any excipients used in the product or other retinoids. According to product labeling, relative contraindications include pregnancy, photosensitive disorder, eczema, sunburn, or concomitant use of other potentially irritating skincare products.</p>
      </sec>
      <sec id="article-919.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>The patient should have a reassessment for efficacy in 12 weeks or sooner if severe adverse effects occur.&#x000a0;According to the American Academy of Dermatology, laboratory&#x000a0;evaluation is recommended for patients with acne and additional signs of androgen excess.<xref ref-type="bibr" rid="article-919.r21">[21]</xref></p>
      </sec>
      <sec id="article-919.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>If the adapalene is applied excessively, marked redness, scaling, or skin discomfort may occur. In addition, according to product labeling, chronic ingestion of the drug may lead to the same adverse&#x000a0;drug reactions&#x000a0;associated with excessive oral intake of vitamin A.&#x000a0;</p>
      </sec>
      <sec id="article-919.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Adapalene is a topical retinoid that is FDA-approved for the treatment of acne vulgaris and used off-label in the treatment of many conditions, including verrucae, molluscum contagiosum, Darier disease, Fox-Fordyce disease, Dowling-Degos disease, photoaging, pigmentary disorders such as melasma and post-inflammatory hyperpigmentation, actinic keratoses, and alopecia areata. The multidimensional acne global grading system, which incorporates primary acne lesions (comedones, papules, and nodules) and associated secondary changes (postinflammatory hyperpigmentation and scarring), is useful in the comprehensive clinical evaluation of acne to guide&#x000a0;appropriate treatment choices.<xref ref-type="bibr" rid="article-919.r22">[22]</xref></p>
        <p>Clinicians and specialists who prescribe this agent and pharmacists interacting with patients must be fully aware of its side effects and contraindications. Pharmacists will also perform thorough medication reconciliation. Due to the lack of epidemiologic data, clinicians should not prescribe adapalene to women during pregnancy or breastfeeding.<xref ref-type="bibr" rid="article-919.r9">[9]</xref><xref ref-type="bibr" rid="article-919.r16">[16]</xref>&#x000a0;Dermatology specialty-trained nursing staff should be on hand to counsel and follow up with patients on adapalene therapy. Nursing should assess patient compliance, answer questions regarding dosing/administration, monitor for adverse events, and promptly alert the prescriber if present. ALl interprofessional team members must maintain meticulous documentation in the patient's medical record and communicate with other team members as necessary so therapeutic modifications can be implemented if appropriate. Collaboration between all these disciplines in an interprofessional team can optimize adapalene therapy while minimizing adverse effects. [Level 5]</p>
      </sec>
      <sec id="article-919.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=919&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=919">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/919/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=919">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-919.s11">
        <title>References</title>
        <ref id="article-919.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stein Gold</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Alexis</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Harper</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>JKL</given-names>
              </name>
            </person-group>
            <article-title>Advances in Acne and Rosacea Therapy.</article-title>
            <source>Semin Cutan Med Surg</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>37</volume>
            <issue>3S</issue>
            <fpage>S63</fpage>
            <page-range>S63-S66</page-range>
            <pub-id pub-id-type="pmid">30192344</pub-id>
          </element-citation>
        </ref>
        <ref id="article-919.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bissonnette</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gratton</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kerrouche</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Canosa</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>The safety and efficacy of four different fixed combination regimens of adapalene 0.1%/benzoyl peroxide 2.5% gel for the treatment of acne vulgaris: results from a randomised controlled study.</article-title>
            <source>Eur J Dermatol</source>
            <year>2018</year>
            <month>Aug</month>
            <day>01</day>
            <volume>28</volume>
            <issue>4</issue>
            <fpage>502</fpage>
            <page-range>502-508</page-range>
            <pub-id pub-id-type="pmid">30187864</pub-id>
          </element-citation>
        </ref>
        <ref id="article-919.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bagatin</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gon&#x000e7;alves</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Sato</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Almeida</surname>
                <given-names>LMC</given-names>
              </name>
              <name>
                <surname>Miot</surname>
                <given-names>HA</given-names>
              </name>
            </person-group>
            <article-title>Comparable efficacy of adapalene 0.3% gel and tretinoin 0.05% cream as treatment for cutaneous photoaging.</article-title>
            <source>Eur J Dermatol</source>
            <year>2018</year>
            <month>Jun</month>
            <day>01</day>
            <volume>28</volume>
            <issue>3</issue>
            <fpage>343</fpage>
            <page-range>343-350</page-range>
            <pub-id pub-id-type="pmid">30105991</pub-id>
          </element-citation>
        </ref>
        <ref id="article-919.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rusu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tanase</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pascu</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Todoran</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Recent Advances Regarding the Therapeutic Potential of Adapalene.</article-title>
            <source>Pharmaceuticals (Basel)</source>
            <year>2020</year>
            <month>Aug</month>
            <day>28</day>
            <volume>13</volume>
            <issue>9</issue>
            <pub-id pub-id-type="pmid">32872149</pub-id>
          </element-citation>
        </ref>
        <ref id="article-919.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Williams</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Pace</surname>
                <given-names>ND</given-names>
              </name>
              <name>
                <surname>DeSesso</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Teratogen update: Topical use and third-generation retinoids.</article-title>
            <source>Birth Defects Res</source>
            <year>2020</year>
            <month>Sep</month>
            <volume>112</volume>
            <issue>15</issue>
            <fpage>1105</fpage>
            <page-range>1105-1114</page-range>
            <pub-id pub-id-type="pmid">32643315</pub-id>
          </element-citation>
        </ref>
        <ref id="article-919.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chivot</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Retinoid therapy for acne. A comparative review.</article-title>
            <source>Am J Clin Dermatol</source>
            <year>2005</year>
            <volume>6</volume>
            <issue>1</issue>
            <fpage>13</fpage>
            <page-range>13-9</page-range>
            <pub-id pub-id-type="pmid">15675886</pub-id>
          </element-citation>
        </ref>
        <ref id="article-919.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kassir</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Karagaiah</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sonthalia</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Katsambas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Galadari</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lotti</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wollina</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Abdelmaksoud</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Grabbe</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Goldust</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Selective RAR agonists for acne vulgaris: A narrative review.</article-title>
            <source>J Cosmet Dermatol</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>19</volume>
            <issue>6</issue>
            <fpage>1278</fpage>
            <page-range>1278-1283</page-range>
            <pub-id pub-id-type="pmid">32100454</pub-id>
          </element-citation>
        </ref>
        <ref id="article-919.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stein Gold</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Baldwin</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Management of Severe Acne Vulgaris With Topical Therapy.</article-title>
            <source>J Drugs Dermatol</source>
            <year>2017</year>
            <month>Nov</month>
            <day>01</day>
            <volume>16</volume>
            <issue>11</issue>
            <fpage>1134</fpage>
            <page-range>1134-1138</page-range>
            <pub-id pub-id-type="pmid">29141062</pub-id>
          </element-citation>
        </ref>
        <ref id="article-919.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sardana</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sehgal</surname>
                <given-names>VN</given-names>
              </name>
            </person-group>
            <article-title>Retinoids: fascinating up-and-coming scenario.</article-title>
            <source>J Dermatol</source>
            <year>2003</year>
            <month>May</month>
            <volume>30</volume>
            <issue>5</issue>
            <fpage>355</fpage>
            <page-range>355-80</page-range>
            <pub-id pub-id-type="pmid">12773802</pub-id>
          </element-citation>
        </ref>
        <ref id="article-919.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thiboutot</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Arsonnaud</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Soto</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and tolerability of adapalene 0.3% gel compared to tazarotene 0.1% gel in the treatment of acne vulgaris.</article-title>
            <source>J Drugs Dermatol</source>
            <year>2008</year>
            <month>Jun</month>
            <volume>7</volume>
            <issue>6 Suppl</issue>
            <fpage>s3</fpage>
            <page-range>s3-10</page-range>
            <pub-id pub-id-type="pmid">18575220</pub-id>
          </element-citation>
        </ref>
        <ref id="article-919.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stein Gold</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Weiss</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rueda</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tanghetti</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Moderate and Severe Inflammatory Acne Vulgaris Effectively Treated with Single-Agent Therapy by a New Fixed-Dose Combination Adapalene 0.3&#x000a0;%/Benzoyl Peroxide 2.5&#x000a0;% Gel: A Randomized, Double-Blind, Parallel-Group, Controlled Study.</article-title>
            <source>Am J Clin Dermatol</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>17</volume>
            <issue>3</issue>
            <fpage>293</fpage>
            <page-range>293-303</page-range>
            <pub-id pub-id-type="pmid">26945741</pub-id>
          </element-citation>
        </ref>
        <ref id="article-919.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Herane</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Orlandi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zegpi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Vald&#x000e9;s</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Anci&#x00107;</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Clinical efficacy of adapalene (differin(&#x000ae;)) 0.3% gel in Chilean women with cutaneous photoaging.</article-title>
            <source>J Dermatolog Treat</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>23</volume>
            <issue>1</issue>
            <fpage>57</fpage>
            <page-range>57-64</page-range>
            <pub-id pub-id-type="pmid">22007702</pub-id>
          </element-citation>
        </ref>
        <ref id="article-919.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tao</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Qian</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>The third-generation retinoid adapalene triggered DNA damage to induce S-phase arrest in HaCat cells.</article-title>
            <source>Fundam Clin Pharmacol</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>34</volume>
            <issue>3</issue>
            <fpage>380</fpage>
            <page-range>380-388</page-range>
            <pub-id pub-id-type="pmid">31808972</pub-id>
          </element-citation>
        </ref>
        <ref id="article-919.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Najafi-Taher</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ghaemi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Amani</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Delivery of adapalene using a novel topical gel based on tea tree oil nano-emulsion: Permeation, antibacterial and safety assessments.</article-title>
            <source>Eur J Pharm Sci</source>
            <year>2018</year>
            <month>Jul</month>
            <day>30</day>
            <volume>120</volume>
            <fpage>142</fpage>
            <page-range>142-151</page-range>
            <pub-id pub-id-type="pmid">29684425</pub-id>
          </element-citation>
        </ref>
        <ref id="article-919.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cunliffe</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Caputo</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dreno</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>F&#x000f6;rstr&#x000f6;m</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Heenen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Orfanos</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Privat</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Robledo Aguilar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Meynadier</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Alirezai</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jablonska</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shalita</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Weiss</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Chalker</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Ellis</surname>
                <given-names>CN</given-names>
              </name>
              <name>
                <surname>Greenspan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Katz</surname>
                <given-names>HI</given-names>
              </name>
              <name>
                <surname>Kantor</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Millikan</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Swinehart</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Swinyer</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Whitmore</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Czernielewski</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Verschoore</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Clinical efficacy and safety comparison of adapalene gel and tretinoin gel in the treatment of acne vulgaris: Europe and U.S. multicenter trials.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>1997</year>
            <month>Jun</month>
            <volume>36</volume>
            <issue>6 Pt 2</issue>
            <fpage>S126</fpage>
            <page-range>S126-34</page-range>
            <pub-id pub-id-type="pmid">9204091</pub-id>
          </element-citation>
        </ref>
        <ref id="article-919.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <article-title>Topical retinoids during pregnancy (continued).</article-title>
            <source>Prescrire Int</source>
            <year>2005</year>
            <month>Jun</month>
            <volume>14</volume>
            <issue>77</issue>
            <fpage>100</fpage>
            <page-range>100-1</page-range>
            <pub-id pub-id-type="pmid">15981398</pub-id>
          </element-citation>
        </ref>
        <ref id="article-919.r17">
          <label>17</label>
          <element-citation publication-type="book">
            <chapter-title>Adapalene</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2023</year>
            <month>5</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">30000483</pub-id>
          </element-citation>
        </ref>
        <ref id="article-919.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hayashi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Akamatsu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Iwatsuki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Shimada-Omori</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kaminaka</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kurokawa</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Kono</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kobayashi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tanioka</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Furukawa</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Furumura</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yamasaki</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Yamasaki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yamamoto</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Miyachi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kawashima</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Japanese Dermatological Association Guidelines: Guidelines for the treatment of acne vulgaris 2017.</article-title>
            <source>J Dermatol</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>45</volume>
            <issue>8</issue>
            <fpage>898</fpage>
            <page-range>898-935</page-range>
            <pub-id pub-id-type="pmid">29782039</pub-id>
          </element-citation>
        </ref>
        <ref id="article-919.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pariser</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Col&#x000f3;n</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Gottschalk</surname>
                <given-names>RW</given-names>
              </name>
            </person-group>
            <article-title>Adapalene 0.1% gel compared to tazarotene 0.1% cream in the treatment of acne vulgaris.</article-title>
            <source>J Drugs Dermatol</source>
            <year>2008</year>
            <month>Jun</month>
            <volume>7</volume>
            <issue>6 Suppl</issue>
            <fpage>s18</fpage>
            <page-range>s18-23</page-range>
            <pub-id pub-id-type="pmid">18575222</pub-id>
          </element-citation>
        </ref>
        <ref id="article-919.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weiss</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Thiboutot</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Hwa</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Graeber</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Long-term safety and efficacy study of adapalene 0.3% gel.</article-title>
            <source>J Drugs Dermatol</source>
            <year>2008</year>
            <month>Jun</month>
            <volume>7</volume>
            <issue>6 Suppl</issue>
            <fpage>s24</fpage>
            <page-range>s24-8</page-range>
            <pub-id pub-id-type="pmid">18575223</pub-id>
          </element-citation>
        </ref>
        <ref id="article-919.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zaenglein</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Pathy</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Schlosser</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Alikhan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Baldwin</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Berson</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Bowe</surname>
                <given-names>WP</given-names>
              </name>
              <name>
                <surname>Graber</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Harper</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Keri</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Leyden</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Reynolds</surname>
                <given-names>RV</given-names>
              </name>
              <name>
                <surname>Silverberg</surname>
                <given-names>NB</given-names>
              </name>
              <name>
                <surname>Stein Gold</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Tollefson</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Weiss</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Dolan</surname>
                <given-names>NC</given-names>
              </name>
              <name>
                <surname>Sagan</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Stern</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Boyer</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Bhushan</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Guidelines of care for the management of acne vulgaris.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2016</year>
            <month>May</month>
            <volume>74</volume>
            <issue>5</issue>
            <fpage>945</fpage>
            <page-range>945-73.e33</page-range>
            <pub-id pub-id-type="pmid">26897386</pub-id>
          </element-citation>
        </ref>
        <ref id="article-919.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bernardis</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Shou</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Barbieri</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>McMahon</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Perman</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Rola</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Streicher</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Treat</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Castelo-Soccio</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>AC</given-names>
              </name>
            </person-group>
            <article-title>Development and Initial Validation of a Multidimensional Acne Global Grading System Integrating Primary Lesions and Secondary Changes.</article-title>
            <source>JAMA Dermatol</source>
            <year>2020</year>
            <month>Mar</month>
            <day>01</day>
            <volume>156</volume>
            <issue>3</issue>
            <fpage>296</fpage>
            <page-range>296-302</page-range>
            <pub-id pub-id-type="pmid">31995147</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
